Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Panbela Therapeutics Inc PBLA

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to... see more

OTCQB:PBLA - Post Discussion

Panbela Therapeutics Inc > PBLA ....vols are minimal at best
View:
Post by Iseneschal on Jan 26, 2024 1:37pm

PBLA ....vols are minimal at best

Re-added sub $3.90

Please refer to sideways channel targets

$3.80 support or bust
Comment by Iseneschal on Jan 26, 2024 1:53pm
I'm broadening my Sideways Channel pattern.... Support at $3.80 and on the top side I'm thinking $4.38 Top side needs a breakout before the close  Cheers !
Comment by Iseneschal on Jan 26, 2024 2:10pm
How's it working out for everyone???? Time to like my prognostications??? Maybe
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities